LongBio Pharma (Suzhou) Co., Ltd. (HKG:1779)
Hong Kong · Delayed Price · Currency is HKD 142.80
+2.80 (2.00%)
Jun 18, 2026, 4:08 PM HKT
LongBio Pharma (Suzhou) Statistics
Total Valuation
HKG:1779 has a market cap or net worth of HKD 10.39 billion. The enterprise value is 10.22 billion.
| Market Cap | 10.39B |
| Enterprise Value | 10.22B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:1779 has 74.19 million shares outstanding.
| Current Share Class | 72.93M |
| Shares Outstanding | 74.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +23.86% |
| Owned by Insiders (%) | 28.19% |
| Owned by Institutions (%) | 23.11% |
| Float | 30.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 66.43 |
| P/TBV Ratio | 66.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.42, with a Debt / Equity ratio of 0.27.
| Current Ratio | 2.42 |
| Quick Ratio | 2.29 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.30 |
| Interest Coverage | -9.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -54.56% |
| Return on Invested Capital (ROIC) | -69.43% |
| Return on Capital Employed (ROCE) | -114.02% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.30M |
| Employee Count | 85 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 568,682 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -182.85M |
| Pretax Income | -195.39M |
| Net Income | -195.39M |
| EBITDA | -178.59M |
| EBIT | -182.85M |
| Earnings Per Share (EPS) | -3.45 |
Balance Sheet
The company has 211.73 million in cash and 42.20 million in debt, with a net cash position of 169.52 million or 2.28 per share.
| Cash & Cash Equivalents | 211.73M |
| Total Debt | 42.20M |
| Net Cash | 169.52M |
| Net Cash Per Share | 2.28 |
| Equity (Book Value) | 156.37M |
| Book Value Per Share | 2.61 |
| Working Capital | 132.00M |
Cash Flow
In the last 12 months, operating cash flow was -134.69 million and capital expenditures -4.88 million, giving a free cash flow of -139.57 million.
| Operating Cash Flow | -134.69M |
| Capital Expenditures | -4.88M |
| Depreciation & Amortization | 4.44M |
| Net Borrowing | -32.31M |
| Free Cash Flow | -139.57M |
| FCF Per Share | -1.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:1779 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1.88% |
| FCF Yield | -1.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |